March 2016 in “The Journal of Urology” The discovery of 5α-reductase deficiency in guevedoces led to the development of important urologic medications.
1 citations
,
September 2016 in “Actas Dermo-Sifiliográficas” 5-alpha reductase inhibitors may cause sexual side effects, breast complications, and other health risks in men with hair loss.
9 citations
,
August 2023 in “Molecules” Two peptides, RMYYY and VMYMI, may be effective anti-inflammatory drugs.
January 2011 in “Reactions Weekly”
28 citations
,
January 2003 in “Urologic oncology” Suppressing certain hormones might help prevent prostate cancer.
19 citations
,
September 2006 in “Journal of Neurophysiology” Neurosteroids help balance brain signals when certain inhibitions are reduced.
November 2010 in “International Journal of Developmental Neuroscience” January 2020 in “Journal of Men s Health” The combination treatment reduced prostate size and improved testosterone deficiency symptoms but was less effective for sexual function.
January 2022 in “Current Enzyme Inhibition” New nonsteroidal molecules can potentially increase dihydrotestosterone in neurons by blocking certain enzymes, without affecting prostate and seminal vesicle weight.
May 2022 in “Current Enzyme Inhibition” Compound 7b is a promising candidate for treating benign prostatic hyperplasia and prostate cancer.
48 citations
,
February 1999 in “PubMed” Finasteride, a drug, can block the seizure-preventing effects of a hormone called progesterone in mice.
Dutasteride reduces prostate cancer risk by 23% in high-risk men.
17 citations
,
June 2012 in “European journal of medicinal chemistry” New steroid compounds effectively inhibit 5α-reductase and may treat hair loss.
9 citations
,
July 2011 in “The Journal of Sexual Medicine” Hair loss drugs like finasteride may cause lasting sexual and mood side effects, and more research is needed to understand these risks.
2 citations
,
August 2016 in “British Journal of Clinical Pharmacology” The document concludes that women should not use 5-alpha-reductase inhibitors due to the risk of birth defects and limited effectiveness.
37 citations
,
May 1997 in “The Journal of Clinical Endocrinology & Metabolism” MK-386 lowers DHT in blood and skin but not in semen.
28 citations
,
May 1994 in “The Journal of Urology” Topical minoxidil not effective for erectile dysfunction treatment.
Finasteride causes reproductive malformations in male rats.
8 citations
,
July 2004 in “The Journal of Clinical Endocrinology & Metabolism” Finasteride is effective for treating BPH but not recommended for prostate cancer prevention.
October 2006 in “Urology” Combination therapy with Finasteride is more effective than alpha-blocker alone for BPH symptoms in small prostate volume.
64 citations
,
June 1995 in “Steroids” Inhibitors of the enzyme 5 alpha-reductase could potentially treat disorders like prostate cancer and baldness.
6 citations
,
July 2016 in “Doklady Biochemistry and Biophysics” GD-23 reduces anxiety by relying on neurosteroid production.
14 citations
,
March 2018 in “Translational Stroke Research” Finasteride helps protect brain in old male rats.
54 citations
,
October 2019 in “Cochrane library” Some drugs may reduce prostatitis symptoms short-term with few side effects.
April 2026 in “Journal of the American Academy of Dermatology” Oral 5-alpha-reductase inhibitors for hair loss don't increase heart risk.
December 2022 in “JAMA network open” 5α-Reductase inhibitors may increase depression risk but not dementia or suicide.
January 2011 in “Shandong yiyao” Finasteride reduces bleeding during prostate surgery.
4 citations
,
August 2021 in “Biomedicine & Pharmacotherapy” 5-alpha reductase inhibitors, like finasteride and dutasteride, may cause depression, but more research is needed to understand why.
October 2008 in “The Journal of Urology” Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.
Finasteride causes reproductive changes in male rats.